EA015342B1 - Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig - Google Patents
Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig Download PDFInfo
- Publication number
- EA015342B1 EA015342B1 EA200870535A EA200870535A EA015342B1 EA 015342 B1 EA015342 B1 EA 015342B1 EA 200870535 A EA200870535 A EA 200870535A EA 200870535 A EA200870535 A EA 200870535A EA 015342 B1 EA015342 B1 EA 015342B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- zeg
- bie
- rgo
- agd
- suz
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000004927 fusion Effects 0.000 title claims abstract description 34
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 6
- 239000012634 fragment Substances 0.000 claims description 27
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 claims description 24
- 102100024304 Protachykinin-1 Human genes 0.000 claims description 24
- 108060003951 Immunoglobulin Proteins 0.000 claims description 15
- 102000018358 immunoglobulin Human genes 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- -1 Ό-penicillamine Chemical compound 0.000 claims description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 4
- 229960002170 azathioprine Drugs 0.000 claims description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000681 leflunomide Drugs 0.000 claims description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- 229960001940 sulfasalazine Drugs 0.000 claims description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 4
- 229960001639 penicillamine Drugs 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 230000003092 anti-cytokine Effects 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000000446 fuel Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 abstract 2
- 238000002347 injection Methods 0.000 description 35
- 239000007924 injection Substances 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 210000003719 b-lymphocyte Anatomy 0.000 description 23
- 201000010099 disease Diseases 0.000 description 23
- 206010067484 Adverse reaction Diseases 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 20
- 230000006838 adverse reaction Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- 230000009266 disease activity Effects 0.000 description 16
- 241000282693 Cercopithecidae Species 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 12
- 230000003285 pharmacodynamic effect Effects 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 239000007929 subcutaneous injection Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000001503 joint Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 210000000207 lymphocyte subset Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 210000003815 abdominal wall Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000001364 causal effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000009228 embryo fetal development Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010022095 Injection Site reaction Diseases 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 231100000279 safety data Toxicity 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101100127285 Drosophila melanogaster unc-104 gene Proteins 0.000 description 2
- 102100040610 Dynein regulatory complex subunit 4 Human genes 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000816970 Homo sapiens Dynein regulatory complex subunit 4 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150002629 TAS1 gene Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010048946 Anal abscess Diseases 0.000 description 1
- 102100033896 Arylsulfatase H Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 208000037397 Fetal Weight Diseases 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000035223 Gestational Weight Gain Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000925530 Homo sapiens Arylsulfatase H Proteins 0.000 description 1
- 101000596016 Homo sapiens TLR adapter interacting with SLC15A4 on the lysosome Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023848 Laryngeal pain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029001 Mediastinal disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100035166 TLR adapter interacting with SLC15A4 on the lysosome Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 102100040791 Zona pellucida-binding protein 1 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74727006P | 2006-05-15 | 2006-05-15 | |
| PCT/US2007/068982 WO2007134326A2 (en) | 2006-05-15 | 2007-05-15 | Methods for treating autoimmune diseases using a taci-ig fusion molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200870535A1 EA200870535A1 (ru) | 2009-04-28 |
| EA015342B1 true EA015342B1 (ru) | 2011-06-30 |
Family
ID=38694783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200870535A EA015342B1 (ru) | 2006-05-15 | 2007-05-15 | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8784812B2 (enExample) |
| EP (1) | EP2035028A2 (enExample) |
| JP (2) | JP2009537563A (enExample) |
| KR (1) | KR20090016707A (enExample) |
| CN (1) | CN101489573B (enExample) |
| AR (1) | AR060935A1 (enExample) |
| AU (1) | AU2007249223B2 (enExample) |
| BR (1) | BRPI0711823A2 (enExample) |
| CA (1) | CA2651791A1 (enExample) |
| EA (1) | EA015342B1 (enExample) |
| EC (1) | ECSP088982A (enExample) |
| IL (1) | IL195243A0 (enExample) |
| MX (1) | MX2008014365A (enExample) |
| NZ (1) | NZ572373A (enExample) |
| UA (1) | UA98462C2 (enExample) |
| WO (1) | WO2007134326A2 (enExample) |
| ZA (1) | ZA200809202B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010125A (es) * | 2007-03-27 | 2010-02-17 | Zymogenetics Inc | Combinacion de inhibicion de estimulador de linfocitos b (blys) y/o inhibicion de ligando inductor de proliferacion (april) e inmunosupresores para tratamiento de enfermedad autoinmunitaria. |
| PT2167038T (pt) * | 2007-06-13 | 2018-06-01 | Zymogenetics Inc | Utilização de proteína de fusão taci-ig, tal como atacicept para o fabrico de um medicamento para tratar lúpus eritematoso |
| DK2233149T3 (en) * | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
| WO2011109280A1 (en) * | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| JP6069210B2 (ja) * | 2010-11-26 | 2017-02-01 | ヘミクス ビー．ヴィ． | 疾患活動性を示す単一の値またはスカラー量を算出するシステム並びに方法、及び、プロセッサシステムに当該方法を実行させるコンピュータプログラム |
| US20170247462A1 (en) | 2014-07-03 | 2017-08-31 | Oklahoma Medical Research Foundation | Treatment of multiple sclerosis and neuromyelitis optica |
| IL297981A (en) * | 2020-05-08 | 2023-01-01 | Alpine Immune Sciences Inc | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CN116897159A (zh) * | 2021-03-31 | 2023-10-17 | 江苏恒瑞医药股份有限公司 | 截短的taci多肽及其融合蛋白和用途 |
| CA3216795A1 (en) * | 2021-05-07 | 2022-11-10 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| CN117203242A (zh) * | 2021-09-30 | 2023-12-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗干燥综合征的方法 |
| TW202432609A (zh) * | 2023-01-31 | 2024-08-16 | 大陸商榮昌生物製藥（煙臺）股份有限公司 | 用ＴＡＣＩ－Ｆｃ融合蛋白治療ＩｇＧ４相關性疾病的方法 |
| WO2025067383A1 (zh) * | 2023-09-28 | 2025-04-03 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002094852A2 (en) * | 2001-05-24 | 2002-11-28 | Zymogenetics, Inc. | Taci-immunoglobulin fusion proteins |
| WO2003014294A2 (en) * | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
| US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
| WO2005005462A2 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
| WO2005042009A1 (en) * | 2003-10-20 | 2005-05-12 | Biogen Idec Ma Inc. | Therapeutic regimens for baff antagonists |
| AU2006201471A1 (en) * | 2000-02-16 | 2006-05-04 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4615974A (en) | 1981-08-25 | 1986-10-07 | Celltech Limited | Yeast expression vectors |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| EP0184576B1 (en) | 1984-12-06 | 1990-06-27 | Fina Research S.A. | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US5637677A (en) | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
| EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| ES2152920T3 (es) | 1990-02-09 | 2001-02-16 | Salk Inst For Biological Studi | Composiciones receptoras de retinoides y metodos. |
| US5208146A (en) | 1990-11-05 | 1993-05-04 | The Regents Of The University Of California | Murine monoclonal anti-idiotype antibodies |
| AU5103293A (en) | 1992-09-14 | 1994-04-12 | Oklahoma State University | Immortalized cells and uses therefor |
| WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5650550A (en) | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
| US5523227A (en) | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
| WO1996018641A1 (en) | 1994-12-15 | 1996-06-20 | Yeda Research And Development Co. Ltd. | Modulators of the function of fas/apo1 receptors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DE19533447C1 (de) | 1995-09-09 | 1996-12-05 | Bbs Kraftfahrzeugtechnik | Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze |
| CA2237039A1 (en) | 1995-11-09 | 1997-05-15 | Zymogenetics, Inc. | Production of gad65 in methylotrophic yeast |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| DE69630710T2 (de) | 1996-03-14 | 2004-09-23 | Human Genome Sciences Inc. | Humaner tumornekrosefaktor delta und epsilon |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| IL128072A0 (en) | 1996-07-17 | 1999-11-30 | Zymogenetics Inc | Preparation of pichia methanolica auxotrophic mutants |
| CA2261151C (en) | 1996-07-17 | 2003-09-16 | Zymogenetics, Inc. | Transformation of pichia methanolica |
| US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
| CA2266439C (en) | 1996-10-25 | 2009-06-16 | Human Genome Sciences, Inc. | Neutrokine .alpha. |
| AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| JP2002504818A (ja) | 1997-06-06 | 2002-02-12 | リジェネロン ファーマシューティカルズ，インコーポレイテッド | リガンドファミリーのｎｔｎ−２メンバー |
| CA2292899A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| WO1999004001A1 (en) | 1997-07-21 | 1999-01-28 | Zymogenetics, Inc. | Tumor necrosis factor receptor ztnfr-5 |
| US6015801A (en) | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| CA2303615A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | April- a novel protein with growth effects |
| TR200000654T2 (tr) | 1997-09-12 | 2000-07-21 | Apotech R & D Sa | KAY-Yeni bir bağışıklık sistemi proteini. |
| DE19831987A1 (de) | 1998-07-16 | 2000-01-20 | Bayer Ag | Diphenylimidazoline |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| CA2357950C (en) | 1998-12-30 | 2013-07-23 | Oligo Therapeutics Inc. | Therapeutic phosphodiesterase inhibitors |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| PL209535B1 (pl) | 1999-01-07 | 2011-09-30 | Zymogenetics Inc | Zastosowanie białka fuzyjnego |
| US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| DK1415659T3 (da) | 1999-01-25 | 2011-10-03 | Biogen Idec Inc | BAFF, inhibitorer og anvendelse deraf i modulering af B-cellerespons |
| CA2363112A1 (en) | 1999-02-23 | 2000-08-31 | Craig A. Rosen | Neutrokine-alpha and neutrokine-alpha splice variant |
| AU4363200A (en) | 1999-04-19 | 2000-11-02 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| US6537540B1 (en) * | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| DK1210425T4 (en) | 1999-08-17 | 2015-08-10 | Apotech R & D Sa | BAFF receptor (BCMA), an immunoregulatory agent |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| EP1666052B1 (en) | 2000-02-16 | 2011-06-08 | Genentech, Inc. | Anti-APRIL monoclonal antibody and its use for the treatment of an immune related disease or cancer |
| SI2857516T1 (sl) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalentna protitelesa in njihove uporabe |
| NZ521629A (en) * | 2000-04-27 | 2004-05-28 | Biogen Inc | TACI as an anti-tumor agent |
| EP1280826B1 (en) | 2000-05-12 | 2007-05-02 | Amgen Inc. | Polypeptides for inhibiting april-mediated b- and t-cell proliferation. |
| EP1310554B1 (en) | 2000-08-11 | 2010-05-26 | Kyowa Hakko Kirin Co., Ltd. | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| DE60138927D1 (de) | 2000-11-07 | 2009-07-16 | Zymogenetics Inc | Menschlicher rezeptor für tumor necrosis factor |
| AU2002238052A1 (en) | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| NZ536908A (en) | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
| US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| AU2006278227B2 (en) | 2005-08-09 | 2011-10-20 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
| MX2008001661A (es) | 2005-08-09 | 2008-04-07 | Ares Trading Sa | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion del activador de transmembrana o interactor del ligando de ciclofilina de modulacion de calcio-ig. |
-
2007
- 2007-05-15 US US11/748,978 patent/US8784812B2/en not_active Expired - Fee Related
- 2007-05-15 AU AU2007249223A patent/AU2007249223B2/en not_active Ceased
- 2007-05-15 MX MX2008014365A patent/MX2008014365A/es not_active Application Discontinuation
- 2007-05-15 KR KR1020087030524A patent/KR20090016707A/ko not_active Ceased
- 2007-05-15 AR ARP070102090A patent/AR060935A1/es unknown
- 2007-05-15 JP JP2009511209A patent/JP2009537563A/ja active Pending
- 2007-05-15 UA UAA200814333A patent/UA98462C2/ru unknown
- 2007-05-15 CN CN2007800262144A patent/CN101489573B/zh not_active Expired - Fee Related
- 2007-05-15 EA EA200870535A patent/EA015342B1/ru not_active IP Right Cessation
- 2007-05-15 NZ NZ572373A patent/NZ572373A/en not_active IP Right Cessation
- 2007-05-15 BR BRPI0711823-6A patent/BRPI0711823A2/pt not_active IP Right Cessation
- 2007-05-15 WO PCT/US2007/068982 patent/WO2007134326A2/en not_active Ceased
- 2007-05-15 CA CA002651791A patent/CA2651791A1/en not_active Abandoned
- 2007-05-15 EP EP07797482A patent/EP2035028A2/en not_active Ceased
-
2008
- 2008-10-27 ZA ZA2008/09202A patent/ZA200809202B/en unknown
- 2008-11-12 IL IL195243A patent/IL195243A0/en not_active IP Right Cessation
- 2008-12-12 EC EC2008008982A patent/ECSP088982A/es unknown
-
2013
- 2013-01-04 JP JP2013000231A patent/JP2013100313A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006201471A1 (en) * | 2000-02-16 | 2006-05-04 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| US20040013674A1 (en) * | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
| WO2002094852A2 (en) * | 2001-05-24 | 2002-11-28 | Zymogenetics, Inc. | Taci-immunoglobulin fusion proteins |
| US20030103986A1 (en) * | 2001-05-24 | 2003-06-05 | Rixon Mark W. | TACI-immunoglobulin fusion proteins |
| WO2003014294A2 (en) * | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
| US20050070689A1 (en) * | 2001-08-03 | 2005-03-31 | Genentech, Inc. | Taci and br3 polypeptides and uses thereof |
| WO2005005462A2 (en) * | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
| WO2005042009A1 (en) * | 2003-10-20 | 2005-05-12 | Biogen Idec Ma Inc. | Therapeutic regimens for baff antagonists |
Non-Patent Citations (1)
| Title |
|---|
| NATURE IMMUNOLOGY, vol. 2, no. 7, 2001, pages 632-636, XP008003924 the whole document * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8784812B2 (en) | 2014-07-22 |
| ZA200809202B (en) | 2009-12-30 |
| MX2008014365A (es) | 2008-11-27 |
| AR060935A1 (es) | 2008-07-23 |
| UA98462C2 (ru) | 2012-05-25 |
| CN101489573A (zh) | 2009-07-22 |
| IL195243A0 (en) | 2011-08-01 |
| ECSP088982A (es) | 2009-01-30 |
| BRPI0711823A2 (pt) | 2012-01-17 |
| AU2007249223B2 (en) | 2012-08-02 |
| JP2013100313A (ja) | 2013-05-23 |
| EP2035028A2 (en) | 2009-03-18 |
| EA200870535A1 (ru) | 2009-04-28 |
| US20070274984A1 (en) | 2007-11-29 |
| WO2007134326A3 (en) | 2008-04-17 |
| CN101489573B (zh) | 2013-05-22 |
| CA2651791A1 (en) | 2007-11-22 |
| NZ572373A (en) | 2012-02-24 |
| WO2007134326A2 (en) | 2007-11-22 |
| JP2009537563A (ja) | 2009-10-29 |
| AU2007249223A1 (en) | 2007-11-22 |
| KR20090016707A (ko) | 2009-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA015342B1 (ru) | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig | |
| EA019998B1 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| US20240287176A1 (en) | Methods of treatment of autoimmune disorders using ilt7 binding proteins | |
| Marasco et al. | Ibuprofen-associated renal dysfunction: pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria | |
| IL188404A (en) | Use of taci-fusion molecules in the preparation of a pharmaceutical composition for the treatment of multiple myeloma | |
| US7842292B2 (en) | Methods for treating B-cell malignancies using a TACI-Ig fusion molecule | |
| CA3230926A1 (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome | |
| WO2024152001A1 (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome | |
| Yukishima et al. | Possible case of elderly-onset intestinal Behçet's disease with trisomy 8 following COVID-19 vaccination exacerbated by COVID-19 infection | |
| HK1128426A (en) | Methods for treating autoimmune diseases using a taci-ig fusion molecule | |
| KR20250162587A (ko) | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 | |
| Kafedziska et al. | Multicenter, Open-Label, Long-term extension to describe the safety of Tocilizumab in patients with early, moderate to severe rheumatoid arthritis | |
| CN117561076A (zh) | 使用ilt7结合蛋白治疗自体免疫病症的方法 | |
| JP2025500352A (ja) | Ｉｌ－１８に対する抗体を要する成人発症スチル病および全身発症型若年性特発性関節炎のための方法および治療 | |
| CN118201629A (zh) | 用于治疗和预防干燥综合征的cd40l特异性tn3衍生的支架 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |